| Date Filed | Type | Description |
| 03/03/2023 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 2,663 shares
@ $0
Sold 3,881 shares
@ $45.25, valued at
$175.6k
|
|
| 06/21/2022 |
4
| Bedrosian Camille L (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $18.29, valued at
$320.1k
|
|
| 06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2022 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Sold 1,657 shares
@ $66.3, valued at
$109.9k
|
|
| 10/18/2021 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Sold 359 shares
@ $81.14, valued at
$29.1k
|
|
| 09/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/23/2021 |
4
| Bedrosian Camille L (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Granted 17,500 options to buy
@ $20.23, valued at
$354k
|
|
| 06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/11/2020 |
4
| Bedrosian Camille L (Director) has filed a Form 4 on RHYTHM PHARMACEUTICALS, INC.|
Txns:
| Granted 37,000 options to buy
@ $28.27, valued at
$1M
|
|
| 12/11/2020 |
3
| Bedrosian Camille L (Director) has filed a Form 3 on RHYTHM PHARMACEUTICALS, INC. |
| 10/16/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/03/2020 |
4
| Bedrosian Camille L (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $16.08, valued at
$402k
|
|
| 09/03/2020 |
3
| Bedrosian Camille L (Director) has filed a Form 3 on Crinetics Pharmaceuticals, Inc. |
| 05/08/2020 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Paid exercise price by delivering 249 shares
@ $66.26, valued at
$16.5k
|
|
| 03/03/2020 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 7,300 shares
@ $0
Granted 5,634 shares
@ $0
Paid exercise price by delivering 1,249 shares
@ $56.08, valued at
$70k
Granted 21,000 options to buy
@ $56.08, valued at
$1.2M
|
|
| 01/31/2020 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Paid exercise price by delivering 1,624 shares
@ $53.23, valued at
$86.4k
|
|
| 10/16/2019 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 1,437 shares
@ $0 |
|
| 05/07/2019 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 1,438 shares
@ $0 |
|
| 03/04/2019 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 7,000 shares
@ $0
Granted 21,500 options to buy
@ $67.55, valued at
$1.5M
|
|
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2018 |
4
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.|
Txns:
| Granted 18,000 shares
@ $0
Granted 88,000 options to buy
@ $55, valued at
$4.8M
|
|
| 01/31/2018 |
3
| Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 3 on Ultragenyx Pharmaceutical Inc. |